Endocrinology and Metabolic Disorders

The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high risk for type 1 diabetes. According to recent Phase II clinical trials, in experimental immunotherapy conducted, the drug has been able to delay the onset of disease for the first time in two years.  According to the American Diabetes Association, Type 1 diabetes is one of the most chronic diseases, affecting about 1.25 million people in the U.S. with nearly 18,000 new Type 1 Diabetes diagnosed cases annually in people under age 20. Diabetes usually begins a year before it is diagnosed. After the research that discovered the...